Biventricular Longitudinal Strain Predict Mortality in COVID-19 Patients

Yuji Xie¹,²†, Lufang Wang¹,²†, Meng Li¹,²†, He Li¹,², Shuangshuang Zhu¹,², Bin Wang¹,², Lin He¹,², Danqing Zhang¹,², Yongxing Zhang¹,², Hongliang Yuan¹,², Chun Wu¹,², Wei Sun¹,², Yanting Zhang¹,², Li Cui¹,²†, Yu Cai¹,², Jing Wang¹,², Yali Yang¹,², Qing Lv¹,², Mingxing Xie¹,²*, Yuman Li¹,²* and Li Zhang¹,²*

¹Department of Ultrasound, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China, ²Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China

Background: Biventricular longitudinal strain has been recently demonstrated to be predictive of poor outcomes in various cardiovascular settings. Therefore, this study sought to investigate the prognostic implications of biventricular longitudinal strain in patients with coronavirus disease 2019 (COVID-19).

Methods: We enrolled 132 consecutive patients with COVID-19. Left ventricular global longitudinal strain from the apical four-chamber views (LV GLS₄CH) and right ventricular free wall longitudinal strain (RV FWLS) were obtained using two-dimensional speckle-tracking echocardiography.

Results: Compared with patients without cardiac injury, those with cardiac injury had higher levels of coagulopathy and inflammatory biomarkers, higher incidence of complications, more mechanical ventilation therapy, and higher mortality. Patients with cardiac injury displayed decreased LV GLS₄CH and RV FWLS, elevated pulmonary artery systolic pressure, and higher proportion of pericardial effusion. Higher biomarkers levels of inflammation and cardiac injury, and the presence of pericardial effusion were correlated with decreases in LV GLS₄CH and RV FWLS. During hospitalization, 19 patients died. Compared with survivors, LV GLS₄CH and RV FWLS were impaired in non-survivors. At a 3-month follow-up after discharge, significant improvements were observed in LV GLS₄CH and RV FWLS. Multivariate Cox analysis revealed that LV GLS₄CH [hazard ratio: 1.41; 95% confidence interval [CI]: 1.08 to 1.84; P = 0.011] and RV FWLS (HR: 1.29; 95% CI: 1.09–1.52; P = 0.003) were independent predictors of higher mortality in patients with COVID-19.

Conclusions: LV GLS₄CH and RV FWLS are independent and strong predictors of higher mortality in COVID-19 patients and can track improvement during the convalescent phase of their illness. Therefore, biventricular longitudinal strain may be crucial for risk stratification and serial follow-up in patients with COVID-19.

Keywords: COVID-19, speckle tracking echocardiography, strain, left ventricular function, right ventricular function
INTRODUCTION

Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a pandemic health crisis. Although, there is increasing awareness of the cardiovascular involvement in COVID-19 disease and its adverse impact on prognosis (1, 2), there is limited data regarding cardiac abnormalities due to SARS-CoV-2 infection. Echocardiography remains the mainstay imaging modality for assessing cardiac function in clinical practice. Recently, left ventricular (LV) and right ventricular (RV) longitudinal strain measured by two-dimensional speckle-tracking echocardiography (2D-STE) has been proposed as more accurate and sensitive indicators of cardiac function in a variety of cardiovascular diseases (3–5). Furthermore, a number of studies confirmed the prognostic value of biventricular longitudinal strain in various clinical settings (6–8). However, the prognostic implications of biventricular longitudinal strain in COVID-19 patients has not been well-established. Accordingly, our study aimed to investigate whether biventricular longitudinal strain were independently predictive of higher mortality in patients with COVID-19 and explore their utility in the follow-up in these patients.

METHODS

Study Population

This single-center, prospective study was performed at the west branch of Union Hospital, Huazhong University of Science and Technology, China, which was a designated hospital to treat patients with COVID-19. We enrolled 169 consecutive adult patients who were diagnosed with COVID-19 according to interim guidance of World Health Organization, from February 11 to March 16, 2020. Considering the presence of cardiac involvement in COVID-19 patients, bedside echocardiography was performed in all patients from three wards managed by the investigators for evaluation of cardiac function. The median time from admission to echocardiographic assessment was 7 days [interquartile range [IQR] 3–11]. Among these patients, three had dilated cardiomyopathy, four had old myocardial infarction, and 30 did not have images of sufficient quality for STE analysis. Finally, 132 patients were recruited in our analysis.

This study was approved by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Ethics Committee (KY-2020-02.06). Written informed consent was waived for all participants with emerging infectious diseases. Patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research.

Data Collection

Demographic characteristics, comorbidities, laboratory findings, medical history, complications, and outcomes for patients during hospitalization were independently reviewed by a team of trained physicians from electronic medical records. The timing of laboratory measurements were within 3 days of echocardiographic examinations with a mean interval of 1 days (IQR: 1–2). Acute cardiac injury was defined as serum levels of cardiac high-sensitivity troponin I (hs-TNI) above the 99th-percentile upper reference limit. The outcome was defined as in-hospital death. The final date of follow-up outcome were April 9, 2020.

Transthoracic Echocardiography

Bedside transthoracic echocardiographic examinations were performed using an EPIQ7C machine (Philips Medical Systems, Andover, MA, USA) at the designated COVID-19 isolation wards or intensive care units (ICU). Forty-six survivors underwent follow-up echocardiographic examinations at 3 months after discharge. All scans were conducted by trained individuals in full personal protective equipment. All echocardiographic images were stored in digital format and analyzed by two independent observers (C.M. and Y.Z.) who were blinded to epidemiological and clinical characteristics, laboratory findings, treatment, and outcomes.

Conventional Echocardiographic Analysis

Left ventricular (LV) and right ventricular (RV) structural and functional parameters were measured based on the guidelines of the American Society of Echocardiography (9). LV mass was assessed by the Devereux’s formula. LV volumes and ejection fraction (EF) were obtained using Simpson’s biplane method. LV diastolic function was assessed by the ratio of peak early-diastolic transmitral inflow velocity (E) to late-diastolic inflow velocity (A), and the ratio of transmitial E to the peak early-diastolic mitral annual velocity (‘E’). We also measured the deceleration time (DT) of the E-wave.

Tricuspid annular plane systolic excursion (TAPSE) was measured on M-mode echocardiography. RV fractional area change (RVFAC) was calculate as (RV end-diastolic area -RV end-systolic area)/end-diastolic area ×100%. Tricuspid lateral annular systolic velocity (S’) was assessed by tissue Doppler imaging from the apical 4-chamber view. Pulmonary artery systolic pressure (PASP) was evaluated using the simplified Bernoulli equation and right atrial pressure assessed on the basis of the size and collapsibility of the inferior vena cava.

STE Analysis

STE analyses were performed using commercially available AutoStrain software (Qlab13, Philips Healthcare, Andover, MA, USA). LV global longitudinal strain (GLS) was calculated by averaging the values obtained in the apical 4-chamber, 3-chamber and 2-chamber views. LV GLS_{4CH} was defined as the mean of the strain values in the six segments of left ventricle from the apical 4-chamber view. LV GLS and GLS_{4CH} were obtained from the standard two-dimensional gray-scale image with a frame rate of 50–70 frames/s. The LV endocardial border was automatically traced at end diastole. Subsequently, the software tracked the endocardial layer throughout the cardiac cycle. The operator could manually adjust the endocardial border if necessary. Right ventricular free wall longitudinal strain (RV FWLS) was obtained from the standard two-dimensional gray-scale image of the RV-focused apical four-chamber view with a frame rate of 50–70 frames/s. The RV endocardial border was automatically traced at end diastole. The software tracked automatically the endocardial
layer throughout the cardiac cycle and the observer may manually adjust the endocardial border if necessary. RV FWLS was calculated as the average of the basal, mid and apical RV free wall segments. Left atrial (LA) endocardial contours were drawn in the apical 4-chamber view with a frame rate of 50–70 frames/s at end systole. The appendage and pulmonary veins were not included. The endocardial border was automatically tracked by software throughout the cardiac cycle. Manual adjustments were performed when tracking was suboptimal. Peak left atrial strain (LAS-peak) was automatically generated from the software. Patients with two or more inadequately tracked segments were removed from analysis. Representative images with LV GLS4CH, RV FWLS and LAS-peak are shown in Figure 1. Absolute values of LV GLS, GLS4CH and RV FWLS were presented in this study for a simpler interpretation, as LV GLS, GLS4CH and RV FWLS were negative values.

**Interobserver and Intraobserver Reproducibility**

Intraobserver and interobserver variability of LV GLS4CH, RV FWLS and LAS-peak were estimated in 20 randomly selected subjects and evaluated by intra-class correlation coefficient (ICC) and Bland-Altman analysis. Intraobserver variability was evaluated by having one observer remeasure after 4 weeks. Interobserver variability was assessed by a second observer who was blinded to the first observer’s measurements.

**Statistical Analysis**

Continuous numeric variables were expressed as mean ± SD or medians (IQR) and compared using a two-sample Student’s t-test and one-way analysis of variance for normally distributed data, or Mann-Whitney test and Kruskal-Wallis test for non-normally distributed data. Categorical variables were expressed as frequency (percentage), and compared using the χ² test or Fisher’s exact test. Spearman’s correlation coefficient were used to evaluate the association between biventricular strain and laboratory findings. Univariate and multivariate Cox regression models were used to assess the predictors of higher mortality. All potential predictors of higher mortality were included into univariate analyses: age, gender, comorbidities, complications, laboratory findings and echocardiographic parameters. Variables with P < 0.05 at

**FIGURE 1** | Biventricular and left atrial longitudinal strain obtained from two-dimensional speckle-tracking echocardiography in COVID-19 patients. (A) Representative image with left ventricular global longitudinal strain from the apical 4-chamber view (LV GLS4CH); (B) Representative image with right ventricular free wall longitudinal strain (RV FWLS); (C) Representative image with peak left atrial strain (LAS-peak).
| Variables | All patients (n = 132) | Without cardiac injury (n = 92) | With cardiac injury (n = 40) | P-value |
|-----------|-----------------------|-------------------------------|-----------------------------|---------|
| **Clinical characteristics** | | | | |
| Age, years | 61 ± 13 | 60 ± 13 | 63 ± 12 | 0.176 |
| Male, n (%) | 68 (51.5%) | 43 (46.7%) | 25 (62.5%) | 0.096 |
| Body mass index, kg/m² | 23.6 ± 2.9 | 23.6 ± 2.9 | 23.8 ± 3.0 | 0.653 |
| Heart rate, beats/min | 86 (80,102) | 86 (80,100) | 90 (80,107) | 0.143 |
| Respiratory rate, breaths/min | 23 (20,30) | 23 (20,30) | 24 (20,29) | 0.966 |
| SBP, mm Hg | 132 (120,144) | 132 (121,144) | 131 (115,146) | 0.735 |
| DBP, mm Hg | 80 (73,87) | 80 (75,89) | 80 (72,85) | 0.235 |
| Smoker, n (%) | 6 (4.5%) | 4 (4.3%) | 2 (5.0%) | 0.591 |
| **Comorbidities** | | | | |
| Hypertension, n (%) | 58 (43.9%) | 38 (41.3%) | 20 (50.0%) | 0.355 |
| Diabetes mellitus, n (%) | 15 (11.4%) | 12 (13.0%) | 3 (7.5%) | 0.533 |
| Obesity, n (%) | 20 (15.2%) | 15 (16.3%) | 5 (12.5%) | 0.767 |
| COPD, n (%) | 5 (3.8%) | 3 (3.3%) | 2 (5.0%) | 0.639 |
| Coronary artery disease, n (%) | 19 (14.4%) | 10 (10.9%) | 9 (22.5%) | 0.080 |
| Chronic kidney disease, n (%) | 1 (0.8%) | 1 (1.1%) | 0 | 1.000 |
| Chronic liver disease, n (%) | 5 (3.8%) | 3 (3.3%) | 2 (5.0%) | 0.639 |
| Arrhythmia, n (%) | 9 (6.8%) | 6 (6.5%) | 3 (7.5%) | 1.000 |
| Malignancy, n (%) | 9 (6.8%) | 6 (6.5%) | 3 (7.5%) | 1.000 |
| **Laboratory findings** | | | | |
| Lymphocyte count, × 10⁹/l | 1.0 (0.6,1.5) | 1.1 (0.7,1.6) | 0.8 (0.4,1.1) | 0.001 |
| D-dimer, mg/l | 1.1 (0.3,3.0) | 1.0 (0.4, 2.8) | 1.6 (0.2, 4.3) | 0.789 |
| PT, s | 13.7 (12.5, 15.0) | 13.2 (12.4, 14.3) | 13.9 (13.2, 15.3) | 0.021 |
| APTT, s | 37.7 (33.1, 44.7) | 36.8 (32.6, 42.1) | 39.5 (38.7, 45.7) | 0.013 |
| CK-MB, U/l | 10 (6, 15) | 9 (5, 15) | 14 (9, 30) | <0.001 |
| hs-TNI, ng/l | 4.1 (2.0, 30.2) | 3.0 (1.5, 4.8) | 85.6 (51.8, 262.1) | <0.001 |
| BNP, pg/ml | 62.4 (31.5, 164.2) | 53.4 (29.3, 120.5) | 130.5 (41.2, 449.0) | 0.019 |
| PaO₂/FIO₂, mm Hg | 233.3 (153.5, 270.7) | 236.4 (156.0, 272.4) | 221.5 (144.7, 274.0) | 0.559 |
| CRP, mg/l | 26.5 (3.8, 68.0) | 15.8 (3.0, 52.6) | 54.0 (18.4, 128.4) | 0.001 |
| PCT, ng/ml | 0.09 (0.05, 0.21) | 0.06 (0.04, 0.14) | 0.23 (0.07, 0.39) | <0.001 |
| IL-6, pg/ml | 4.1 (2.0, 21.0) | 3.9 (1.2, 7.8) | 11.2 (2.9, 23.4) | 0.039 |
| **Treatments** | | | | |
| Antiviral therapy, n (%) | 122 (92.4%) | 86 (93.5%) | 36 (90.0%) | 0.737 |
| Antibiotic therapy, n (%) | 98 (74.2%) | 64 (69.6%) | 34 (85.0%) | 0.062 |
| Glucocorticoid therapy, n (%) | 57 (43.5%) | 30 (32.6%) | 27 (67.5%) | <0.001 |
| Intravenous immune globulin, n (%) | 49 (37.1%) | 30 (32.6%) | 19 (47.5%) | 0.104 |
| Anticoagulant therapy, n (%) | 62 (47.0%) | 41 (44.5%) | 21 (52.5%) | 0.401 |
| Diuretics, n (%) | 35 (26.5%) | 21 (22.8%) | 14 (35.9%) | 0.145 |
| Beta-blockers, n (%) | 26 (19.7%) | 19 (20.7%) | 7 (17.5%) | 0.676 |
| Alpha-blockers, n (%) | 2 (1.5%) | 1 (1.1%) | 1 (2.5%) | 0.516 |
| Calcium channel blockers, n (%) | 40 (30.3%) | 28 (30.4%) | 12 (30.0%) | 0.960 |
| ACE inhibitor/ARB, n (%) | 9 (6.9%) | 7 (7.8%) | 2 (5.0%) | 0.840 |
| Oxygen therapy, n (%) | 117 (88.6%) | 80 (87.0%) | 37 (92.5%) | 0.523 |
| High-flow oxygen, n (%) | 72 (55.0%) | 45 (49.5%) | 27 (67.5%) | 0.056 |
| Mechanical ventilation, n (%) | 32 (24.2%) | 15 (16.3%) | 17 (42.5%) | 0.001 |
| IMV, n (%) | 22 (16.7%) | 10 (10.9%) | 12 (30.0%) | 0.007 |
| NIMV, n (%) | 10 (7.6%) | 5 (6.4%) | 5 (12.5%) | 0.170 |
| ICU admission, n (%) | 25 (18.9%) | 13 (14.1%) | 12 (30.0%) | 0.032 |
| **Complications** | | | | |
| Acute kidney injury, n (%) | 20 (15.2%) | 6 (6.5%) | 14 (35.0%) | <0.001 |
| ARDS, n (%) | 49 (37.1%) | 28 (30.4%) | 21 (52.5%) | 0.016 |

(Continued)
univariate analysis were entered into multivariate Cox regression models. Owing to smaller patients with endpoints, there may exist an over-fitting issue. Therefore, to avoid problems of overfitting the data, a separate Cox proportional hazard model including clinical variables and each of biventricular function parameters (LV GLS\textsubscript{CH}, TAPSE, RVFAC, and RV FWLS), was used to determine the independent predictors of higher mortality. The model performance was assessed by Akaike Information Criterion (AIC). Receiver operator characteristic (ROC) curves were used to determine the optimal cutoff value of LA, LV and RV function parameters for detecting poor outcomes. Kaplan-Meier survival curves were plotted and compared using the log-rank test. All statistical analyses were performed using a SPSS version 20.0 (SPSS Inc., Chicago, Illinois), and a two-sided value of $P < 0.05$ was considered as statistically significant.
RESULTS

Clinical Characteristics

Clinical characteristics of patients with COVID-19 are presented in Table 1. The mean age of patients was 61 ± 13 years, and 68 (51.5%) were male. Of the 132 patients, 40 (30.3%) patients displayed acute cardiac injury. Compared with patients without cardiac injury, those with cardiac injury had lower lymphocyte count, and higher levels of coagulopathy and inflammatory biomarkers [prothrombin time (PT), activated partial thromboplastin time (APTT), C-reactive protein (CRP), procalcitonin (PCT) and interleukin 6 (IL-6)]. The levels of creatine kinase muscle-brain (CK-MB) and B-type natriuretic peptide levels were also higher in patients with cardiac injury than those without. Additionally, patients with cardiac injury were more likely to develop acute kidney injury and

Table 1

| Variables                        | All patients (n = 132) | Moderate (n = 50) | Severe (n = 35) | Critical (n = 47) | p-value |
|----------------------------------|-----------------------|------------------|-----------------|------------------|---------|
| Age, years                       | 61 ± 13               | 59 ± 12          | 62 ± 15         | 63 ± 12          | 0.241   |
| Male, n (%)                      | 68 (51.5%)            | 20 (40.0%)       | 19 (54.3%)      | 29 (61.7%)       | 0.093   |
| Body mass index, kg/m²           | 23.6 ± 2.9            | 23.6 ± 2.6       | 23.4 ± 3.0      | 23.9 ± 3.2       | 0.810   |
| Heart rate, beats/min            | 91 ± 17               | 90 ± 16          | 88 ± 15         | 94 ± 19          | 0.216   |
| Respiratory rate, breaths/min    | 25 ± 6                | 24 ± 6           | 24 ± 5          | 25 ± 7           | 0.707   |
| SBP, mm Hg                       | 134 ± 18              | 134 ± 17         | 133 ± 20        | 131 ± 17         | 0.742   |
| DBP, mm Hg                       | 81 ± 12               | 82 ± 10          | 81 ± 14         | 80 ± 12          | 0.767   |
| **Left heart**                   |                       |                  |                 |                  |         |
| LA dimension, mm                | 34.3 ± 5.4            | 34.3 ± 4.9       | 35.2 ± 4.7      | 34.2 ± 6.5       | 0.466   |
| LV dimension, mm                | 45.5 ± 4.9            | 44.9 ± 4.6       | 46.4 ± 4.8      | 45.8 ± 5.1       | 0.526   |
| IVS, mm                          | 9.6 ± 1.3             | 9.7 ± 1.1        | 9.6 ± 1.9       | 9.6 ± 1.0        | 0.629   |
| PW, mm                           | 8.8 ± 1.9             | 9.2 ± 1.1        | 8.2 ± 2.7*      | 9.0 ± 1.7        | 0.049   |
| LVM, g                           | 144.3 ± 36.1          | 143.7 ± 35.6     | 148.0 ± 40.9    | 144.7 ± 33.6     | 0.861   |
| DT, ms                           | 204.4 ± 53.7          | 209.3 ± 60.4     | 190.0 ± 48.8    | 209.8 ± 46.5     | 0.176   |
| E/A ratio                        | 0.8 (0.7, 1.1)        | 0.8 (0.7, 1.1)   | 0.9 (0.7, 1.3)  | 0.8 (0.7, 1.0)   | 0.515   |
| E/e ratio                        | 8.4 (6.8, 10.6)       | 8.4 (6.5, 10.0)  | 8.8 (6.3, 10.6) | 8.0 (6.9, 10.9)  | 0.891   |
| LVEDV, ml/m²                     | 52.2 ± 16.1           | 55.0 ± 15.6      | 53.0 ± 17.5     | 48.9 ± 14.4      | 0.321   |
| LVESV, ml/m²                     | 17.5 (15.2, 22.9)     | 17.5 (15.2, 22.8)| 18.6 (15.8, 24.2)| 16.2 (13.8, 23.1)| 0.724   |
| LVEF, %                          | 62.8 ± 6.9            | 63.4 ± 7.7       | 62.5 ± 7.4      | 62.9 ± 5.8       | 0.882   |
| LV GLS LCH, %                    | 18.9 (16.8, 20.9)     | 20.1 (18.2, 22.0)| 19.0 (17.3, 21.9)| 17.0 (15.7, 18.6)*< 0.001 |
| LAS-peak, %                     | 33.7 ± 7.6            | 31.9 ± 7.9       | 35.8 ± 8.1      | 32.0 ± 10.2      | 0.146   |
| Moderate-severe MR, n (%)        | 2 (1.5%)              | 0 (0)            | 0 (0)           | 2 (4.3%)         | 0.090   |
| **Right heart**                  |                       |                  |                 |                  |         |
| RA dimension, mm                | 35.5 ± 4.6            | 34.7 ± 4.9       | 36.4 ± 3.4      | 35.9 ± 5.1       | 0.209   |
| RV dimension, mm                | 34.0 (30.6, 36.4)     | 33.3 (29.8, 35.8) | 34.4 (32.4, 36.8) | 34.0 (30.7, 36.6) | 0.485   |
| TAPSE, mm                       | 22.2 ± 3.8            | 22.8 ± 3.8       | 22.6 ± 3.5      | 20.8 ± 3.7*      | 0.019   |
| RVFAC, %                        | 47.2 (41.6, 51.2)     | 49.3 (42.0, 52.2) | 45.5 (40.8, 51.2)| 46.9 (40.9, 50.3)| 0.255   |
| S’, cm/s                        | 13.3 (11.9, 15.0)     | 14.0 (12.0, 15.0)| 14.0 (12.0, 16.4)| 12.9 (11.0, 15.0)| 0.301   |
| RV FWLS, %                      | 22.7 (19.2, 25.6)     | 23.9 (20.1, 26.2)| 23.6 (19.8, 26.1)| 20.2 (18.1, 24.0)*< 0.015 |
| Moderate-severe TR, n (%)        | 4 (3.0%)              | 0 (0)            | 0 (0)           | 4 (8.5%)         | 0.016   |
| PASP, mm Hg                      | 36 ± 14               | 30 ± 11          | 39 ± 14*        | 39 ± 15*         | 0.037   |
| **Prognosis**                   |                       |                  |                 |                  |         |
| Discharge, n (%)                 | 113 (85.6%)           | 50 (100.0%)      | 33 (97.1%)      | 30 (62.5%)< 0.001 |
| Death, n (%)                     | 19 (14.4%)            | 0 (0)            | 1 (2.9%)        | 18 (37.5%)< 0.001 |

Values are mean ± SD, n, %, median (interquartile range); "*P < 0.05, severe or critical vs. moderate; "#P < 0.05, critical vs. severe. COVID-19, coronavirus disease 2019; DBP, diastolic blood pressure; DT, peak E deceleration time of mitral inflow; IVS, interventricular septum; LA, left atrial; LAS, left atrial strain; LV, left ventricular; LV GLS LCH, left ventricular global longitudinal strain derived from the apical four-chamber view; LVEDVI, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end systolic volume index; LVM, left ventricular mass; MR, mitral regurgitation; PASP, pulmonary artery systolic pressure; PW, posterior wall of left ventricle; RA, right atrial; RV, right ventricular; RV FWLS, right ventricular free wall longitudinal strain; RVFAC, RV fractional area change; SBP, systolic blood pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation. LV GLS LCH and RV FWLS values are absolute values.
acute respiratory distress syndrome (ARDS), and be admitted to ICU. And they were more likely to receive treatment with high-flow oxygen and mechanical ventilation, and had higher mortality.

**Echocardiographic Characteristics**

LV GLSCH measurements were obtained in all patients. LV GLS measurements were feasible in 99 patients. LV GLSCH was strongly correlated with LV GLS ($r = 0.93$, $P < 0.001$). Furthermore, No significant difference between LV GLSCH and LV GLS was observed in our study ($19.1 \pm 2.9\%$ vs. $19.1 \pm 2.7\%$, $P = 0.885$) (Supplementary Figure 1). Therefore, we used LV GLSCH to assess the LV GLS in 132 patients with COVID-19 to obtain larger sample size. We consider it is reasonable to use LV GLSCH as a surrogate for LV GLS during the epidemic of COVID-19 to allow rapid image acquisition, improve feasibility in LV strain analysis and reduce contagion exposure duration to healthcare worker. Echocardiographic characteristics of COVID-19 patients are described in Table 2. Eleven patients had pericardial effusion. Patients with cardiac injury displayed lower TAPSE, LV GLSCH, and RV FWLS, higher PASP, and higher proportion of pericardial effusion than those without cardiac injury. However, there was no significant difference in left and right heart size, LAS-peak, LV volumes, mass and diastolic function, LVEF; and moderate–severe MR and TR between these two groups. In addition, LV GLSCH and RV FWLS was lower in patients with ARDS than those without ($18.1 \pm 2.7\%$ vs. $19.7 \pm 3.3\%$, $P = 0.004$; $21.0 \pm 4.9\%$ vs. $23.7 \pm 4.7\%$, $P = 0.003$;

**TABLE 4 | Clinical and echocardiographic characteristics of survivors and non-survivors with COVID-19.**

| Variables | All patients (n = 132) | Survivor (n = 113) | Non-survivor (n = 19) | P-value |
|-----------|------------------------|-------------------|-----------------------|---------|
| **Clinical characteristics** | | | | |
| Age, years | $61 \pm 13$ | $61 \pm 13$ | $64 \pm 13$ | 0.556 |
| Male, n (%) | 68 (51.5%) | 54 (47.8%) | 14 (73.7%) | 0.037 |
| Body mass index, kg/m$^2$ | 23.6 ± 2.9 | 23.6 ± 2.9 | 23.7 ± 3.5 | 0.701 |
| Heart rate, beats/min | 91 ± 17 | 90 ± 16 | 96 ± 22 | 0.092 |
| Respiratory rate, breaths/min | 25 ± 6 | 24 ± 5 | 28 ± 8 | 0.059 |
| SBP, mm Hg | 134 ± 18 | 133 ± 18 | 134 ± 16 | 0.914 |
| DBP, mm Hg | 81 ± 12 | 81 ± 12 | 78 ± 14 | 0.245 |
| **Left heart** | | | | |
| LA dimension, mm | 34.2 (31.7, 37.0) | 34.2 (31.6, 36.9) | 35.7 (31.7, 37.7) | 0.602 |
| LV dimension, mm | 45.8 (42.3, 49.0) | 45.9 (42.3, 49.3) | 45.8 (41.7, 48.4) | 0.751 |
| IVS, mm | 9.6 (8.9, 10.4) | 9.6 (9.0, 10.4) | 9.6 (9.2, 10.1) | 0.962 |
| PW, mm | 9.2 (8.3, 9.9) | 9.0 (8.1, 9.9) | 9.4 (8.9, 9.7) | 0.350 |
| LVM, g | 143.2 (116.0, 168.5) | 143.0 (121.5, 169.3) | 148.7 (114.1, 170.4) | 0.824 |
| DT, ms | 202.0 (163.9, 235.0) | 206.5 (162.5, 229.0) | 195.0 (164.0, 222.0) | 0.488 |
| E/A ratio | 0.8 (0.7, 1.1) | 0.8 (0.7, 1.1) | 0.9 (0.7, 1.4) | 0.218 |
| E/e’ ratio | 8.4 (6.8, 10.6) | 8.1 (6.8, 10.1) | 8.9 (7.1, 11.7) | 0.274 |
| LVEDVI, ml/m$^2$ | 49.8 (39.2, 59.3) | 51.1 (41.1, 63.0) | 38.9 (33.1, 38.9) | 0.043 |
| LVESVI, ml/m$^2$ | 17.5 (15.2, 22.9) | 18.2 (15.5, 23.3) | 14.2 (10.6, 23.5) | 0.077 |
| LVEF, % | 63.2 (59.1, 68.0) | 63.3 (59.0, 68.0) | 63.4 (59.9, 67.8) | 0.655 |
| LV GLSCH, % | 18.9 (16.8, 20.9) | 19.3 (17.3, 21.6) | 16.0 (14.7, 16.9) | <0.001 |
| LAS-peak, % | 33.7 (27.6, 37.9) | 33.4 (27.0, 39.5) | 30.2 (27.1, 36.7) | 0.155 |
| Moderate-severe MR, n (%) | 2 (1.5%) | 0 (0) | 2 (10.5%) | 0.020 |

| Variables | All patients (n = 132) | Survivor (n = 113) | Non-survivor (n = 19) | P-value |
|-----------|------------------------|-------------------|-----------------------|---------|
| **Right heart** | | | | |
| RA dimension, mm | 35.7 (32.4, 38.2) | 35.1 (32.1, 37.7) | 37.6 (34.2, 39.1) | 0.030 |
| RV dimension, mm | 34.0 (30.6, 36.4) | 33.2 (30.3, 35.7) | 35.8 (32.0, 41.0) | 0.022 |
| TAPSE, mm | 22.2 (19.1, 25.2) | 22.3 (20.2, 25.4) | 19.0 (17.1, 21.1) | 0.001 |
| RVFAC, % | 47.2 (41.6, 51.2) | 48.2 (42.0, 52.0) | 43.2 (37.8, 49.0) | 0.008 |
| S’, cm/s | 13.3 (11.9, 15.7) | 14.0 (12.0, 15.7) | 11.7 (10.0, 14.7) | 0.017 |
| RV FWLS, % | 22.7 (19.2, 25.6) | 23.6 (20.0, 26.1) | 18.0 (17.3, 20.6) | <0.001 |
| Moderate-severe TR, n (%) | 4 (3.0%) | 2 (1.8%) | 3 (15.8%) | 0.018 |
| PASP, mm Hg | 33 (24, 47) | 31 (24, 47) | 47 (32, 60) | 0.041 |

Values are mean ± SD, n (%), median (interquartile range). COVID-19, coronavirus disease 2019; DBP, diastolic blood pressure; DT, peak E deceleration time of mitral inflow; IVS, interventricular septum; LA, left atrial; LAS, left atrial strain; LV, left ventricular; LV GLSCH, left ventricular global longitudinal strain derived from the apical four-chamber view; LVEDVI, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end systolic volume index; LVM, left ventricular mass; MR, mitral regurgitation; PASP, pulmonary artery systolic pressure; PW, posterior wall of left ventricle; RA, right atrial; RV, right ventricular; RV FWLS, right ventricular free wall longitudinal strain; RVFAC, RV fractional area change; SBP, systolic blood pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation. LV GLSCH and RV FWLS values are absolute values.
respectively), whereas LAS-peak did not differ between patients with ARDS and without (33.0 ± 8.2% vs. 33.4 ± 8.2%, P = 0.793).

According to the seventh version of the guidelines on the Diagnosis and Treatment of COVID-19 by the National Health Commission, COVID-19 severity is classified as mild, moderate, severe and critical types (10). There were 50 moderate, 35 severe, and 47 critical patients in our study. Our results revealed that critical group had decreased LV GLS_{4CH}, RV FWLS, and TAPSE, elevated PASP, higher proportion of moderate-severe TR, and higher mortality compared with moderate and severe groups. There was no significant difference in LVEF, LAS-peak, RVFAC and S′ among the moderate, severe, and critical groups (Table 3).

At the time of the echocardiographic examinations, 32 patients were intubated. 117 (88.6%) patients were in oxygen therapy. 72 (55.0%) patients were treated with high-flow oxygen. Compared with patients who did not require mechanical ventilation, those who required mechanical ventilation had impaired LV GLS_{4CH}, RV FWLS, and elevated PASP, whereas LVEF and LAS-peak were not different between these two groups (Supplementary Table 1).

During hospitalization, 19 patients died. Compared with survivors, non-survivors displayed dilated right heart chamber, impaired TAPSE, RVFAC, S′, RV FWLS and LV GLS_{4CH}, higher proportion of moderate-severe MR and TR, and higher PASP. In contrast, left heart chamber dimension, LAS-peak, LV wall thickness, mass and diastolic function, and LVEF were similar between survivors and non-survivors (Table 4).

### Follow-Up Study in COVID-19 Patients Who Were Alive

Forty-six survivors were followed up at 3 months after discharge (Table 5). We observed significant improvements in LV GLS_{4CH}, RV FWLS, and LAS-peak (Figure 2), and a decrease in PASP in recovered patients, whereas LVEF and conventional RV function parameters (TAPSE, S′ and RVFAC) were not different from the baseline values (P > 0.05).

### Correlation of Biventricular Function With Cardiac Injury and Inflammatory Marker

A decrease in LV GLS_{4CH} weakly correlated with decreased lymphocyte count (r = 0.37, P < 0.001), and elevated levels of CRP (r = −0.39, P < 0.001), PCT (r = −0.31, P = 0.001), IL-6 (r = −0.28, P = 0.041), CK-MB (r = −0.17, P = 0.044), hs-TNI (r = −0.30, P = 0.001), D-dimer (r = −0.24, P = 0.012) and APTT (r = −0.26, P = 0.003) (Supplementary Figure 2). A reduction in RV FWLS had weak correlations with higher levels of CRP (r = −0.29, P = 0.001), PCT (r = −0.33, P = 0.001), CK-MB (r = −0.21, P = 0.018), hs-TNI (r = −0.43, P < 0.001), APTT (r = −0.26, P = 0.003), and PT (r = −0.30, P = 0.001) (Supplementary Figure 3). Additionally, decreased LV GLS_{4CH} and RV FWLS were also related to the presence of pericardial effusion (r = −0.217, P = 0.012; r = −0.339, P < 0.001, respectively). In contrast, LAS-peak and LVEF had no significant correlation with biomarkers levels of inflammation, coagulopathy, and cardiac injury (P > 0.05 for all).

### Predictors of Mortality in Patients With COVID-19

A univariate Cox regression analysis showed that elevated level of hs-TNI, ARDS, LV GLS_{4CH}, RV FWLS, TAPSE, and RVFAC were
associated with higher risk of mortality (Table 6). Whereas, LAS-peak, LVEF and $S'$ were not predictive of death. The multivariate Cox analysis models revealed that hs-TNI elevation and ARDS continued to be of prognostic significance. LV GLS$_{4CH}$ [hazard ratio (HR): 1.41, 95% confidence intervals (CI): 1.08-1.84; $P$ = 0.011], RV FWLS (HR: 1.29, 95% CI: 1.09-1.52; $P$ = 0.003), TAPSE (HR: 0.82, 95% CI: 0.69-0.98; $P$ = 0.031), and RVFAC (HR: 0.92, 95% CI: 0.85-0.99; $P$ = 0.032) were independent predictive of higher risk of death. The Cox models using LV GLS$_{4CH}$ (AIC = 131) or LV FWLS (AIC = 122) were observed to predict higher mortality more accurately than that with TAPSE (AIC = 134), RVFAC (AIC = 134) or traditional risk model (AIC = 138) (Table 6).

LAS-peak, LV GLS$_{4CH}$, RV FWLS, conventional RV function parameters and LVEF were entered into ROC analysis to estimate probability of in-hospital death. Impaired LV GLS$_{4CH}$ and RV FWLS were associated with higher mortality (Figure 3). Areas under the curve were 0.85 for LV GLS$_{4CH}$ and 0.80 for RV FWLS. The optimal cutoff value of LV GLS$_{4CH}$ for detection of increased mortality was $–17.9\%$ with sensitivity of 94.7% and specificity of 65.8%. The best cutoff value of RV FWLS for identification of death was $–22.9\%$ (sensitivity, 94.4%; specificity, 55.7%).

Kaplan-Meier survival curves of biventricular longitudinal strain for mortality are presented in Figure 4. When stratified by cutoff values, LV GLS$_{4CH}$ lower than 17.9 % or RV FWLS lower than 22.9% were associated with higher mortality ($P < 0.001$) (Figures 4A,B). Patients with below cutoff LV GLS$_{4CH}$ and RV FWLS had the worst prognosis compared those with above cutoff LV GLS$_{4CH}$ and RV FWLS (Figure 4C). To determine the relationship between levels of hs-TNI, cardiac function parameters and mortality, a contour plot was performed. Our findings revealed that decreased LV GLS$_{4CH}$, RV FWLS, RVFAC, and TAPSE were associated with increased death, which was pronounced in patients with higher levels of hs-TNI (Figure 5).

**Reproducibility**

The intraobserver and interobserver reproducibility of LV GLS$_{4CH}$, RV FWLS and LAS-peak are summarized in Supplemental Table 2. The intraobserver and interobserver reproducibility of LV GLS$_{4CH}$, RV FWLS, and LAS-peak were high.

**DISCUSSION**

To the best of our knowledge, our study is the first to systematically assess cardiac structure and function in COVID-19 patients using both conventional echocardiography and 2D-STE. This study demonstrates that patients with cardiac injury had higher levels of coagulopathy and inflammatory biomarkers, higher incidence of complications, more treatment with mechanical ventilation, higher mortality, and lower LV GLS$_{4CH}$ and RV FWLS than those without cardiac injury. Compared with survivors, non-survivors displayed reduced biventricular longitudinal strain, and comparable LVEF. At a 3-month follow-up after discharge, we identify that biventricular longitudinal strain can track clinical improvement in the convalescent phase. Importantly, LV GLS$_{4CH}$ and RV FWLS are powerful predictors of higher mortality in patients with COVID-19. Therefore, biventricular longitudinal strain may be essential for risk stratification and serial follow-up in patients with COVID-19.

**Biventricular Function in Patients With COVID-19**

SARS-CoV-2 are known to result in the acute and chronic damage of the cardiovascular system (11, 12). Although several recent studies have demonstrated that 5.2%-23% patients with COVID-19 suffered myocardial injury from the infection (12–14), there are limited echocardiographic data regarding the cardiac abnormalities. Prior report highlights the significance of assessing cardiac function of hospitalized COVID-19 patients (15).

Despite the importance and extensive use of LVEF in routine clinical practice, there are several limitations of its application. First, it depends on geometric assumptions and loading conditions. Moreover, it could not reflect myocardial contractility (16). Finally, LVEF may have considerable inter- and intra-observer variability. Accordingly, LVEF may not be an optimal index to detect myocardial impairment. Novel, more sensitive indices for cardiac dysfunction at an earlier stage are required. Recently, LV and RV longitudinal strain have been recommended as sensitive and early indicators of
TABLE 6 | Predictors of mortality in patients with COVID-19 by cox proportional hazard model.

|                      | Univariate Cox regression | Model 1 ARDS + hs-TNI | Model 2 ARDS + hs-TNI + LV GLS<sub>4CH</sub> | Model 3 ARDS + hs-TNI + TAPSE | Model 4 ARDS + hs-TNI + RVFAC | Model 5 ARDS + hs-TNI + RV FWLS |
|----------------------|---------------------------|-----------------------|-----------------------------------------------|-------------------------------|-------------------------------|----------------------------------|
|                      | HR (95% CI) p-value       | HR (95% CI) p-value   | HR (95% CI) p-value                          | HR (95% CI) p-value           | HR (95% CI) p-value           | HR (95% CI) p-value              |
| Age, years           | 1.02 (0.99, 1.06) 0.354   |                       |                                               |                               |                               |                                  |
| Male (yes vs. no)    | 3.06 (1.01, 9.22) 0.048   |                       |                                               |                               |                               |                                  |
| Hypertension (yes vs. no) | 2.58 (0.98, 6.79) 0.055  |                       |                                               |                               |                               |                                  |
| Diabetes mellitus (yes vs. no) | 0.38 (0.05, 2.86) 0.349 |                       |                                               |                               |                               |                                  |
| Obesity, n (%)       | 0.88 (0.25, 3.04) 0.837   |                       |                                               |                               |                               |                                  |
| Coronary artery disease (yes vs. no) | 1.49 (0.53, 4.18) 0.447 |                       |                                               |                               |                               |                                  |
| Malignancy (yes vs. no) | 1.99 (0.46, 8.65) 0.359  |                       |                                               |                               |                               |                                  |
| Arrhythmia (yes vs. no) | 1.09 (0.25, 4.79) 0.909  |                       |                                               |                               |                               |                                  |
| ARDS (yes vs. no)    | 7.50 (2.18, 25.80) 0.001  | 5.52 (1.59, 19.22) 0.007 | 4.27 (1.20, 15.21) 0.025 | 5.43 (1.50, 19.65) 0.010 | 5.90 (1.68, 20.71) 0.006 | 3.77 (1.04, 13.67) 0.044 |
| Elevated CK-MB (yes vs. no) | 0.20 (0.03, 1.49) 0.116  |                       |                                               |                               |                               |                                  |
| Elevated hs-TNI (yes vs. no) | 8.13 (2.69, 24.51) <0.001 | 6.23 (2.04, 19.00) 0.001 | 3.53 (1.06, 11.80) 0.041 | 3.70 (1.12, 12.23) 0.032 | 4.36 (1.36, 13.95) 0.013 | 4.28 (1.36, 13.47) 0.013 |
| Elevated BNP (yes vs. no) | 0.70 (0.57, 4.17) 0.397  |                       |                                               |                               |                               |                                  |
| PaO<sub>2</sub>-FiO<sub>2</sub>, mmHg | 1.00 (0.98, 1.01) 0.599  |                       |                                               |                               |                               |                                  |
| Mechanical ventilation (yes vs. no) | 2.20 (0.89, 5.42) 0.088  |                       |                                               |                               |                               |                                  |
| ACE inhibitor/ARB (yes vs. no) | 0.59 (0.08, 4.45) 0.610  |                       |                                               |                               |                               |                                  |
| Pericardial effusion (yes vs. no) | 1.93 (0.56, 6.68) 0.299  |                       |                                               |                               |                               |                                  |
| E/e' ratio           | 1.02 (0.90, 1.16) 0.794   |                       |                                               |                               |                               |                                  |
| LVEDVI, ml/m<sup>2</sup> | 0.95 (0.90, 1.00) 0.070   |                       |                                               |                               |                               |                                  |
| LVESVI, ml/m<sup>2</sup> | 0.90 (0.84, 1.03) 0.163   |                       |                                               |                               |                               |                                  |
| LVM, g               | 1.00 (0.99, 1.01) 0.771   |                       |                                               |                               |                               |                                  |
| LVEF, %              | 1.02 (0.95, 1.10) 0.607   |                       |                                               |                               |                               |                                  |
| LV GLS<sub>4CH</sub>, % | 1.70 (1.30, 2.23) <0.001  | 1.41 (1.08, 1.84) 0.011 |                       |                                               |                               |                                  |
| LAS-peak, %          | 0.96 (0.90, 1.03) 0.217   |                       |                                               |                               |                               |                                  |
| TAPSE, mm            | 0.81 (0.70, 0.93) 0.003   | 0.82 (0.69, 0.98) 0.031 |                       |                                               |                               |                                  |
| RVFAC, %             | 0.89 (0.82, 0.97) 0.007   |                       |                                               |                               |                               |                                  |
| S', cm/s             | 0.83 (0.68, 1.01) 0.058   | 0.92 (0.85, 0.99) 0.032 |                       |                                               |                               |                                  |
| RV FWLS, %           | 1.32 (1.15, 1.50) <0.001  |                       |                                               |                               |                               |                                  |
| AIC / /                              | 138             | 131             | 134             | 134             | 122             |                                  |

ACE, angiotensin-converting enzyme; AIC, Akaike Information Criterion; ARB, angiotensin II receptor blockers; ARDS, acute respiratory distress syndrome; BNP, B-type natriuretic peptide; CI, confidence interval; CK-MB, creatine kinase muscle-brain; COVID-19, coronavirus disease 2019; FIO<sub>2</sub>, fraction of inspiration oxygen; HR, hazard ratio; hs-TNI, high-sensitivity troponin I; LAS, left atrial strain; LV GLS<sub>4CH</sub>, left ventricular global longitudinal strain derived from the apical four-chamber view; LVEDVI, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end systolic volume index; LVM, left ventricular mass; PaO<sub>2</sub>, partial pressure of oxygen; RV FWLS, right ventricular free wall longitudinal strain; RVFAC, right ventricular fractional area change; TAPSE, tricuspid annular plane systolic excursion. CK-MB ≥ 25 U/l was defined as elevated CK-MB; hs-TNI ≥ 26.2 ng/ml was defined as elevated hs-TNI; BNP ≥ 100 pg/ml was defined as elevated BNP.
COVID-19 infection (regarding the cardiac impairment in patients diagnosed with subclinical cardiac dysfunction (17). They are measurements of myocardial deformation, and objective parameters with excellent reproducibility and high feasibility. We previously found that COVID-19 patients had impaired RV FWLS (18). However, there are no data regarding the use of LV GLS4CH in patients with COVID-19. In the present study, we identified that COVID-19 patients exhibited significantly impaired LV GLS4CH and RV FWLS, while no difference was found in LVEF. Moreover, impaired biventricular longitudinal strain appeared to be worse in critically ill patients or those who required mechanical ventilation therapy. These findings are in agreement with the study of SARS, which revealed that the diminished LV performance was worse in patients who needed treatment with mechanical ventilation (19). In a study of 28 patients with acute myocarditis, reduced LV GLS correlated with the amount of oedema, and added important information on the diagnosis and degree of myocardial dysfunction, especially in patients with preserved LVEF (20). Recently, there are increasing data regarding the cardiac impairment in patients diagnosed with COVID-19 infection (21–24). The mechanisms of cardiac injury are uncertain but likely involve direct viral injury, aggravation of a systemic inflammatory response, hypoxemia, destabilized coronary plaques and microthrombosis (25). Consistent with this postulation, the correlations of diminished LV GLS4CH and RV FWLS with elevated biomarkers levels of inflammation, coagulopathy, and cardiac injury were observed in our study. Besides, we found that patients with cardiac injury displayed higher proportion of pericardial effusion than those without cardiac injury. Moreover, decreased LV GLS4CH and RV FWLS were also correlated with the presence of pericardial effusion, suggesting that the presence of pericardial effusion or pericarditis have a major influence on the biventricular strain values.

In addition to myocardial injury, RV function was predisposed to impairment owing to increased RV afterload from ARDS, hypoxic pulmonary vasoconstriction, pulmonary microthrombi, and endothelial and microvascular injury (26). RV dilation and dysfunction may also affect the LV function and aggravate LV dysfunction by ventricular interdependence and paradoxical septum. The reductions in LV GLS4CH and RV FWLS are important in COVID-19 patients, as owing to overlapping symptoms of dyspnea, the diagnosis of myocardial involvement may be challenging. These findings are also particularly significant to the majority of COVID-19 patients with a normal LVEF.

The Utility of Biventricular Longitudinal Strain During the Follow-Up Study

At 3-month follow-up after discharge, significant improvements in biventricular longitudinal strain were identified in our study, indicating that depressed LV and RV performance may be reversible on disease recovery when the acute inflammatory response waned. Consistent with our results, Li et al. showed that impaired LV function appeared to be reversible at 30-day follow-up study in 46 patients with SARS (19). In another follow-up observation of 11 COVID-19 patients with LV dysfunction, Dr. Churchill and colleagues demonstrated resolution of LV abnormalities after a median of 14 days (27). However, LVEF and conventional RV function parameters did not show significant improvements with therapy in our study. These findings suggest biventricular longitudinal strain may be more sensitive to detect subtle myocardial improvement compared to other standard echocardiographic parameters. Our results demonstrate the superiority of biventricular longitudinal strain over conventional echocardiographic indices during the follow-up in patients with COVID-19.

The Prognostic Value of Biventricular Longitudinal Strain in COVID-19 Patients

To the best of our knowledge, this may be the first study to investigate whether biventricular longitudinal strain were associated with fatal outcomes in COVID-19 patients. Indeed, in the present study, patients with diminished LV GLS4CH and RV FWLS were at higher risk of death. Our findings reveal that biventricular longitudinal strain serve as novel imaging biomarkers that predicts higher mortality in patients with COVID-19. Consistent with these results, our study previously revealed that RV FWLS was an independent predictor of poor outcomes in COVID-19 patients (18). Similarly, Argulian et al. showed that RV dilation was predictive of in-hospital mortality in patients with COVID-19. (28) Another observation was reported by Szekely et al. (21), which demonstrated increased RV end diastolic area was significantly associated with mortality.

In addition, LV GLS has presented additional prognostic significance over LVEF in a range of cardiovascular disorders (6, 29). However, the prognostic implication of LV GLS4CH in COVID-19 patients remained unknown. Our findings showed that LV GLS4CH was predictive of higher mortality in COVID-19 patients, whereas LVEF was not. This is in

---

**TABLE 1**

| Variables     | AUC (95% CI) | P-value | Sensitivity (%) | Specificity (%) |
|---------------|-------------|---------|----------------|-----------------|
| RV FWLS (%)  | 0.89(0.71, 0.88) | < 0.001 | 94.4           | 55.7            |
| LV GLS4CH (%)| 0.85(0.78, 0.90) | < 0.001 | 94.7           | 65.8            |

**FIGURE 3** ROC curves of biventricular longitudinal strain for adverse clinical outcome. LV GLS4CH, left ventricular global longitudinal strain from the apical four-chamber view; RV FWLS, Right ventricular free wall longitudinal strain.
Kaplan-Meier survival curves showing the association of biventricular longitudinal strain and higher mortality. Kaplan-Meier curves in COVID-19 patients stratified by the cutoff value of LV GLS_{4CH} (A) and RV FWLS (B). Kaplan-Meier curves reveal that COVID-19 patients below cutoff LV GLS_{4CH} and RV FWLS have the highest mortality. LV GLS_{4CH} and RV FWLS values are absolute values. LV GLS_{4CH} (+), below cutoff LV GLS_{4CH}; LV GLS_{4CH} (–), above cutoff LV GLS_{4CH}; RV FWLS (+), below cutoff RV FWLS; RV FWLS (–), above cutoff RV FWLS.

FIGURE 5 | Contour plot of survival probability in hospitalized patients with COVID-19. Decreased LV GLS_{4CH} (A), RV FWLS (B), RV FAC (C), and TAPSE (D) are associated with higher mortality, which is pronounced in patients with higher levels of hs-TNI.

Contradistinction to a recent study in patients with COVID-19 in Israel, which reported that lower LVEF was associated with mortality (21). However, in the previous study (21), patients were older, and have higher rate of male, hypertension, diabetes mellitus, and obesity. The current data indicates that LV GLS_{4CH} and RV FWLS are not only more sensitive markers of subclinical myocardial impairment, but also powerful and independent predictors of higher mortality. Therefore, biventricular longitudinal strain could help risk stratification of COVID-19 patients.

Clinical Implications
LVEF is a key determinant in clinical decision-making in various diseases. However, it is relatively indiscriminant within the normal range. Novel biventricular longitudinal strain may be of particular clinical significance in COVID-19 patients with relatively normal LVEF. Our data showed LV GLS_{4CH} and RV FWLS, rather than LVEF, were strong predictors of higher risk of mortality. Furthermore, biventricular longitudinal strain can provide highly useful and clinically relevant information during the follow-up in patients with COVID-19. The present...
study revealed the important clinical implication of biventricular longitudinal strain, as measurements of LV GLS\textsubscript{ACH} and RV FWLS are fast and non-invasive methods that can be easily obtained from bedside echocardiography. More importantly, they can identify subclinical myocardial impairment, help detect in higher risk of COVID-19 patients and serially follow patients.

**Limitations**

Our study has several limitations that should be mentioned. First, as 2D-STE depends on image quality, severe and critically ill patients with inadequate echocardiographic images might have been underrepresented. Furthermore, 2D-STE analysis was performed using Qlab software in our study, so the results in the present study may not be apply to other software algorithms because 2D-STE parameters are hampered by inter-vendor variability. Although our study exclude dilated cardiomyopathy and old myocardial infarction that may significant lead to impaired biventricular longitudinal strain, patients had hypertension or coronary artery diseases, who had underlying medical condition that could have affected strain values. In addition, our study used the LV GLS\textsubscript{ACH} rather than the LV GLS to estimate LV myocardial longitudinal function during the epidemic of COVID-19 to allow rapid image acquisition and reduce contagion exposure duration to healthcare worker. Another limitation was that only a small proportion of COVID-19 patients had follow-up echocardiographic data, though improvement in biventricular longitudinal strain was noted. Finally, the study was a single-center study with a relatively limited sample size. Therefore, further large multi-center studies are needed to confirm the results in the present study.

**CONCLUSIONS**

Our study demonstrates that LV GLS\textsubscript{ACH} and RV FWLS are independently predicative of higher mortality, providing incremental prognostic implications over conventional echocardiographic parameters in patients with COVID-19. We also identify that biventricular longitudinal strain provide highly relevant information regarding the recovery of cardiac function when the acute inflammatory response subsided. Therefore, biventricular longitudinal strain are valuable non-invasive parameters in risk stratification and serial follow-up of patients with COVID-19.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81727805, 81922033, 81401432).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2020.632434/full#supplementary-material
the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. (2015) 28:1–39.e14. doi: 10.1093/ehjci/eju140.10.03

10. Guideline for the Diagnosis and Treatment of (2019). Novel Coronavirus (2019-nCoV) Infected Pneumonia. Available online at: http://news.cyol.com/app/2020-02/05/content_1833703.htm (accessed March 4, 2020).

11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7

12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

13. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. (2020) 8:475–81. doi: 10.1016/S2213-2600(20)30079-5

14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9. doi: 10.1001/jama.2020.1585

15. Gackowski A, Lipczyńska M, Lipiec P, Szymański P. Expert opinion of the working group on echocardiography of the polish cardiac society on performing echocardiographic examinations during COVID-19 pandemic. Kardiol Pol. (2020) 78:357–63. doi: 10.33963/KP.15265

16. Patel RB, Vaduganathan M, Greene SJ, Butler J. Nomenclature in heart failure: a call for objective, reproducible, biologically-driven terminology. Eur J Heart Fail. (2018) 20:1379–81. doi: 10.1002/ejhf.1231

17. Nauta JF, Jin X, Hummel YM, Voors AA. Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal. Eur J Heart Fail. (2018) 20:1636–8. doi: 10.1002/ejhf.1326

18. Li Y, Li H, Zhu S, Xie Y, Wang B, He L, et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. JACC Cardiovasc Imaging. (2020) 13:2287–99. doi: 10.1016/j.jcmg.2020.04.014

19. Li SS, Cheng CW, Fu CL, Chan YH, Lee MP, Chan JW, et al. Left ventricular performance in patients with severe acute respiratory syndrome. Circulation. (2003) 108:1798–803. doi: 10.1161/01.CIR.0000094737.21775.32

20. Logstrup BB, Nielsen JM, Kim WY, Poulsen SH. Myocardial oedema in acute myocarditis detected by echocardiographic 2D myocardial deformation analysis. Eur Heart J Cardiovasc Imaging. (2016) 17:1018–26. doi: 10.1093/ehjci/jew302

21. Székely Y, Lichter Y, Taib P, Banai A, Hochstadt A, Merdler I, et al. The spectrum of cardiac manifestations in coronavirus disease 2019 (COVID-19) - a systematic echocardiographic study. Circulation. (2020) 142:342–53. doi: 10.1161/CIRCULATIONAHA.120.047971

22. Sud K, Vogel B, Bohra C, Garg V, Talebi S, Lerakis S, et al. Echocardiographic findings in COVID-19 patients with significant myocardial injury. J Am Soc Echocardiogr. (2020) 33:1054–5. doi: 10.1016/j.echo.2020.05.030

23. Zhang L, Wang B, Zhou J, Kirkpatrick J, Xie M, Johri AM, Bedside focused cardiac ultrasound in COVID-19 infection from the wuhan epicenter: the role of cardiac point of care ultrasound (POCUS), limited transthoracic echocardiography and critical care echocardiography. J Am Soc Echocardiogr. (2020) 33:676–82. doi: 10.1016/j.echo.2020.04.004

24. Jain SS, Liu Q, Raikhelkar J, Fried J, Elias P, Poterucha TJ. Indications and findings on transthoracic echocardiogram in COVID-19. J Am Soc Echocardiogr. (2020) 33:1278–84. doi: 10.1016/j.echo.2020.06.009

25. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. (2020) 17:259–60. doi: 10.1038/s41569-020-0360-5

26. Park JF, Banerjee S, Umar S. In the eye of the storm: the right ventricle in COVID-19. Palm Circ. (2020) 20:45894020936660. doi: 10.1177/2045894020936660

27. Churchill TW, Bertrand PB, Bernard S, Namawiyam M, Churchill J, Croussillat D, et al. Echocardiographic features of COVID-19 illness and association with cardiac biomarkers. J Am Soc Echocardiogr. (2020) 33:1053–4. doi: 10.1016/j.echo.2020.05.028

28. Argulian E, Sud K, Vogel B, Bohra C, Garg VP, Talebi S, et al. Right ventricular dilation in hospitalized patients with COVID-19 infection. JACC Cardiovasc Imaging. (2020) 13:2459–61. doi: 10.1016/j.jcmg.2020.05.010

29. Caspar T, Fichot M, Ohana M, El Ghannudi S, Morel O, Ohlmann P. Late detection of left ventricular dysfunction using two-dimensional and three-dimensional speckle-tracking echocardiography in patients with history of nonsevere acute myocarditis. J Am Soc Echocardiogr. (2017) 30:756–62. doi: 10.1016/j.echo.2017.04.002

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.